DXCM - Conference and earnings call announcements

Participation advances the company’s vision and regulatory pathway for earlier intervention, screening for prediabetes and Type 2 diabetes and empowerment Dexcom (NASDAQ:DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating real-world evidence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722426337

Now through Sept. 19, people in the U.S. and Canada from 2 years and older living with all types of diabetes and prediabetes can apply for a once-in-a-lifetime opportunity to raise diabetes awareness on a global scale. Selected candidates will be given a global platform to champion the diabetes community while starring in Dexcom's 2025 World Diabetes Day campaign. DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the launch of its first open call in the U.S. and Canada in search of the next diabetes advocates. Those selected will experience a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale this World Diabete

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 43rd annual J.P. Morgan Healthcare Conference on January 13, 2025. The live presentation is scheduled to begin at approximately 12:00 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people ma

DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 42nd annual J.P. Morgan Healthcare Conference on January 8, 2024. The live presentation is scheduled to begin at approximately 12:45 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference. About DexCom, Inc. DexCom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring systems. Headquartered in San Diego, Calif., and with operations across Euro

DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 41st annual J.P. Morgan Healthcare Conference on January 9, 2023. The live presentation is scheduled to begin at approximately 2:15 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference. About DexCom, Inc. DexCom, Inc. empowers people to take real-time control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations acro

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming virtual investor conferences: Brice Bobzien, Vice President, Finance will present on behalf of the company at the SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 5:00pm (EST). Jereme Sylvain, Executive Vice President and Chief Financial Officer will present on behalf of the company at the Citi 2022 Healthcare Services, Medtech, Tools and HCIT Virtual Conference on Wednesday, February 23, 2022 at 10:15am (EST). Links to the webcasts will be available on the Dexcom Investor Relations website at investors.dexcom.com/ and will b

DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 40th annual J.P. Morgan Healthcare Conference on January 10, 2022. The live presentation, which will occur virtually, is scheduled to begin at approximately 10:30 AM EST and will be concurrently webcast. The link to the webcast will be available on the Dexcom IR website at investors.dexcom.com by navigating to "Events and Presentations." About DexCom, Inc. DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged a

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conference: Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the 33rd Annual Piper Sandler Virtual Healthcare Conference on Wednesday, December 1, 2021 at 2:30 PM (ET). The presentation will be concurrently webcast. The link to the webcast will be available on the Dexcom IR website at investors.dexcom.com by navigating to "Events and Presentations." About DexCom, Inc. Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headqu

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming virtual investor conferences: Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present on behalf of the company at the Wells Fargo 2021 Virtual Healthcare Conference on Friday, September 10, 2021 at 2:00pm (EST). Quentin Blackford, Chief Operating Officer, will present on behalf of the company at the Morgan Stanley 19th Annual Healthcare Conference on Monday, September 13, 2021 at 2:00pm (EST). Links to the webcasts will be available on the Dexcom Investor Relations website at investors.dexcom.com/ and will be archived there for future referen

Conference programming reaffirms Dexcom CGM as central to improved diabetes management Showcases benefits of Dexcom CGM for broader populations beyond those on mealtime insulin Demonstrates the impact of Dexcom real-time CGM for inpatient monitoring DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today featured research and data presentations that will headline the 81st Scientific Sessions of the American Diabetes Association (ADA) virtual conference held June 25-29, 2021. "Year over year it is remarkable to see the growing body of research and data that continues to show CGM is central to optimal d

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference: Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present on behalf of the company at the William Blair 41st Annual Growth Stock Conference to be held virtually on Tuesday, June 1, 2021 at 12:00pm (CDT). The presentation will be available via live webcast. The webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com/ and will be archived there for future reference. About DexCom, Inc. DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CG

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 39th annual J.P. Morgan Healthcare Conference on January 11, 2021. The live presentation, which will occur virtually, is scheduled to begin at approximately 11:40 AM EST and will be concurrently webcast. The link to the webcast will be available on the Dexcom IR website at investors.dexcom.com by navigating to “Events and Presentations.” About DexCom, Inc. DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Die